Become a Pet Trainer in the Newest Mabinogi “P.E.T.” Update Arriving on July 16
13.7.2020 16:00:00 EEST | Business Wire | Press release
Mabinogi, Nexon’s free-to-play fantasy MMORPG will be receiving the delightful new “P.E.T.” update on July 16! Following the introduction of Mabinogi’s exciting furry pets in the “My Little Pet” update, the World of Erinn is changing with the addition of more powerful Fynn Pets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005083/en/
Mabinogi P.E.T. (Graphic: Business Wire)
While the recent “My Little Pet” update expanded activities for pets embarking on expeditions to explore the world of Erinn, the P.E.T. update challenges players with a new Pet Training talent to discover the Power of the Fynn and set out to unlock stronger Fynn Pets.
To unlock Fynn Pets, players need to sync their main pet with other pets using Fynn Sync. The Fynn Pet will receive the Power of the Fynn, increasing a pet’s max level, inventory, summoning time and more! With the update, players can also defeat monsters to obtain Fynni Gems and bloom the Fynni Gems through the Fynni Blossoming skill to gain a Fynni Pet. Fynni Pets can accompany players similar to other pets, and can be used for Fynn Sync.
Existing Pet Perks will also be revamped to increase efficiency. Additionally, all pets will now be able to use a set of new more powerful Pet Perks, including:
- Wild Frenzy: Increases a pet’s minimum, maximum and critical damage for a set period while the perk is activated. An additional attack will reach several enemies within a certain radius of the target.
- Frozen Earth: Ice cold Fynni will gather and play as a pet covers the ground with a sheet of ice. The icy Fynnis will cling to enemies nearby while the skill is activated, stunning and causing damage.
- Wings of Haste: Speeds up a pet’s ability for a set duration while activated. Pet owner’s speed will also increase.
While harvesting Capybara Fur and helping Heulfryn, players will encounter peculiar children, Pinkie and Katell. They speak of secrets of the Fynni imbued within pets and monsters as well as how to control them through the power of Fynn. Learn of Mag Mell, the last resting place of the Fairies.
Fynn Pets add another magical element to the already charming world of Mabinogi, as players utilize special pet abilities and perks that can be activated during various battles across Erinn, and more.
To learn more about Mabinogi “P.E.T.” Update, visit the official website and follow @mabinogi on Facebook for the latest updates.
Assets: Mabinogi P.E.T. Update Trailer
Social Media: Facebook / Twitter / Instagram / Twitch / YouTube / Discord
About Mabinogi http://mabinogi.nexon.net/
Released in 2008, Mabinogi is an immersive free-to-play MMORPG world where mystical adventures await. Create anime-inspired heroes with thousands of customization options, such as hairstyles, facial features and outfits. Select from dozens of talents ranging from professional gunslingers and archers to musicians, tailors and cooks. Players can enjoy the game on their own terms, taking the perilous path of an adventurer or build a thriving business using unique trade skills.
About Nexon America Inc. http://www.nexon.com
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005083/en/
Contact information
Nexon America
Cynthia Lezama
clezama@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom